Type I and II IFNs inhibit merkel cell carcinoma via modulation of the merkel cell polyomavirus T antigens

Cancer Research

Volumn 72, Issue 8, 2012, Pages 2120-2128

  Willmes, Christoph ^a   Adam, Christian ^a   Alb, Miriam ^a   Völkert, Lena ^a   Houben, Roland ^a   Becker, Jürgen C ^b   Schrama, David ^a,b  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON; INTERFERON; MULTIFERON; PROMYELOCYTIC LEUKEMIA PROTEIN; UNCLASSIFIED DRUG; VIRUS LARGE T ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE G0 PHASE; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; MERKEL CELL POLYOMAVIRUS; MERKEL CELL TUMOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR REGRESSION;

ANIMALS; ANTIGENS, VIRAL, TUMOR; CARCINOMA, MERKEL CELL; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INTERFERON TYPE I; INTERFERON-GAMMA; MERKEL CELL POLYOMAVIRUS; MICE; MICE, INBRED NOD; POLYOMAVIRUS INFECTIONS; SKIN NEOPLASMS;

EID: 84860153632     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-2651     Document Type: Article

References (48)

1. Hodgson NC. Merkel cell carcinoma: changing incidence trends. J Surg Oncol 2005;89:1-4. (Pubitemid 40075960)
2. Becker JC, Schrama D, Houben R. Merkel cell carcinoma. Cell Mol Life Sci 2009;66:1-8.
3. Rollison DE, Giuliano AR, Becker JC. New virus associated with merkel cell carcinoma development. J Natl Compr Canc Netw 2010;8:874-80.
4. Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 2008;319:1096-100. (Pubitemid 351300792)
5. Kassem A, Schopflin A, Diaz C, Weyers W, Stickeler E, Werner M, et al. Frequent detection of Merkel cell polyomavirus in human Merkel cell carcinomas and identification of a unique deletion in the VP1 gene. Cancer Res 2008;68:5009-13.
6. Becker JC, Houben R, Ugurel S, Trefzer U, Pfohler C, Schrama D. MC polyomavirus is frequently present in Merkel cell carcinoma of European patients. J Invest Dermatol 2009;129:248-50.
7. Shuda M, Feng H, Kwun HJ, Rosen ST, Gjoerup O, Moore PS, et al. T antigen mutations are a human tumor-specific signature for Merkel cell polyomavirus. Proc Natl Acad Sci U S A 2008;105:16272-7.
8. Houben R, Shuda M, Weinkam R, Schrama D, Feng H, Chang Y, et al. Merkel cell polyomavirus-infected Merkel cell carcinoma cells require expression of viral T antigens. J Virol 2010;84:7064-72.
9. Houben R, Adam C, Baeurle A, Hesbacher S, Grimm J, Angermeyer S, et al. An intact retinoblastoma protein-binding site in Merkel cell polyomavirus large T antigen is required for promoting growth of Merkel cell carcinoma cells. Int J Cancer 2012;130:847-56.
10. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1957;147:258-67.
11. Bracarda S, Eggermont AM, Samuelsson J. Redefining the role of interferon in the treatment of malignant diseases. Eur J Cancer 2010;46:284-97.
12. Ank N, Paludan SR. Type III IFNs: new layers of complexity in innate antiviral immunity. Biofactors 2009;35:82-7.
13. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 2004;75:163-89. (Pubitemid 38174573)
14. Kuhr T, Burgstaller S, Apfelbeck U, LinkeschW, Seewann H, Fridrik M, et al. A randomized study comparing interferon (IFN alpha) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronicphase chronic myeloid leukemia (CML). Leuk Res 2003;27:405-11. (Pubitemid 36287202)
15. Kirkwood JM, Tawbi HA, Tarhini AA, Moschos SJ. Does pegylated interferon alpha-2b confer additional benefit in the adjuvant treatment of high-risk melanoma? Nat Clin Pract Oncol 2009;6:70-1.
16. Plettenberg A, Kern P, Dietrich M, Meigel W. [Recombinant interferon alpha-2A in the treatment of HIV-associated Kaposi sarcoma. Longterm results]. Med Klin (Munich) 1990;85:647-52.
17. Lublin F. History of modern multiple sclerosis therapy. J Neurol 2005;252 Suppl 3:iii3-9. (Pubitemid 41355778)
18. Razonable RR. Antiviral drugs for viruses other than human immunodeficiency virus. Mayo Clin Proc 2011;86:1009-26.
19. Co JK, Verma S, Gurjav U, Sumibcay L, Nerurkar VR. Interferon-alpha and -beta restrict polyomavirus JC replication in primary human fetal glial cells: implications for progressive multifocal leukoencephalopathy therapy. J Infect Dis 2007;196:712-8. (Pubitemid 47293854)
20. Abend JR, Low JA, Imperiale MJ. Inhibitory effect of gamma interferon on BK virus gene expression and replication. J Virol 2007;81:272-9. (Pubitemid 44975167)
21. Gasparovic ML, Maginnis MS, O'Hara BA, Dugan AS, Atwood WJ. Modulation of PML protein expression regulates JCV infection. Virology 2009;390:279-88.
22. Krasagakis K, Kruger-Krasagakis S, Tzanakakis GN, Darivianaki K, Stathopoulos EN, Tosca AD. Interferon-alpha inhibits proliferation and induces apoptosis of merkel cell carcinoma in vitro. Cancer Invest 2008;26:562-8. (Pubitemid 351918576)
23. Matsushita E, Hayashi N, Fukushima A, Ueno H. [Evaluation of treatment and prognosis of Merkel cell carcinoma of the eyelid in Japan]. Nippon Ganka Gakkai Zasshi 2007;111:459-62.
24. Biver-Dalle C, Nguyen T, Touze A, Saccomani C, Penz S, Cunat-Peultier S, et al. Use of interferon-alpha in two patients with Merkel cell carcinoma positive for Merkel cell polyomavirus. Acta Oncol 2011;50:479-80.
25. Ronan SG, Green AD, Shilkaitis A, Huang TS, Das Gupta TK. Merkel cell carcinoma: in vitro and in vivo characteristics of a new cell line. J Am Acad Dermatol 1993;29:715-22. (Pubitemid 23327971)
26. Leonard JH, Dash P, Holland P, Kearsley JH, Bell JR. Characterisation of four Merkel cell carcinoma adherent cell lines. Int J Cancer 1995;60:100-7.
27. VanGele M, Leonard JH, Van Roy N, Van Limbergen H, Van Belle S, Cocquyt V, et al. Combined karyotyping, CGH and M-FISH analysis allows detailed characterization of unidentified chromosomal rearrangements in Merkel cell carcinoma. Int J Cancer 2002;101:137-45. (Pubitemid 34970905)
28. Gresser I, Belardelli F, Maury C, Tovey MG, Maunoury MT. Anti-tumor effects of interferon in mice injected with interferon-sensitive and interferon-resistant friend leukemia cells. IV. Definition of optimal treatment regimens. Int J Cancer 1986;38:251-7. (Pubitemid 16043603)
29. Soderberg O, Gullberg M, Jarvius M, Ridderstrale K, Leuchowius KJ, Jarvius J, et al. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods 2006;3:995-1000. (Pubitemid 44782698)
30. Krejcova D, Prochazkova J, Kubala L, Pachernik J. Modulation of cell proliferation and differentiation of human lung carcinoma cells by the interferon-alpha. Gen Physiol Biophys 2009;28:294-301.
31. Toker C. Trabecular carcinoma of the skin. Arch Dermatol 1972;105:107-10.
32. Mori Y, Hashimoto K, Tanaka K, Cui CY, Mehregan DR, Stiff MA. A study of apoptosis in Merkel cell carcinoma: an immunohistochemical, ultrastructural, DNA ladder, and TUNEL labeling study. Am J Dermatopathol 2001;23:16-23. (Pubitemid 32116331)
33. Suzuki T, Orba Y, Okada Y, Sunden Y, Kimura T, Tanaka S, et al. The human polyoma JC virus agnoprotein acts as a viroporin. PLoSPathog 2010;6:e1000801.
34. Johnson EM. Structural evaluation of new human polyomaviruses provides clues to pathobiology. Trends Microbiol 2010;18:215-23.
35. Carvalho T, Seeler JS, Ohman K, Jordan P, Pettersson U, Akusjarvi G, et al. Targeting of adenovirus E1A and E4-ORF3 proteins to nuclear matrix-associated PML bodies. J Cell Biol 1995;131:45-56.
36. Everett RD. DNA viruses and viral proteins that interact with PML nuclear bodies. Oncogene 2001;20:7266-73. (Pubitemid 33105015)
37. Everett RD, Rechter S, Papior P, Tavalai N, Stamminger T, Orr A. PML contributes to a cellular mechanism of repression of herpes simplex virus type 1 infection that is inactivated by ICP0. J Virol 2006;80:7995-8005. (Pubitemid 44182300)
38. Everett RD, Chelbi-AlixMK.PMLandPMLnuclear bodies: implications in antiviral defence. Biochimie 2007;89:819-30. (Pubitemid 47008945)
39. Yanase N, Kanetaka Y, Mizuguchi J. Interferon-alpha-induced apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-dependent and -independent manner. Oncol Rep 2007;18:1031-8.
40. Crowder C, Dahle O, Davis RE, Gabrielsen OS, Rudikoff S. PML mediates IFN-alpha-induced apoptosis in myeloma by regulating TRAIL induction. Blood 2005;105:1280-7. (Pubitemid 40170904)
41. Maher SG, Romero-Weaver AL, Scarzello AJ, Gamero AM. Interferon: cellular executioner or white knight?CurrMedChem2007;14:1279-89. (Pubitemid 46746361)
42. Stawowczyk M, Van SS, Kumar KP, Reich NC. The interferon stimulated gene 54 promotes apoptosis. J Biol Chem 2011;286:7257-66.
43. Potu H, Sgorbissa A, Brancolini C. Identification of USP18 as an important regulator of the susceptibility to IFN-alpha and drug-induced apoptosis. Cancer Res 2010;70:655-65.
44. Wellbrock C, Weisser C, Hassel JC, Fischer P, Becker J, Vetter CS, et al. STAT5 contributes to interferon resistance of melanoma cells. Curr Biol 2005;15:1629-39. (Pubitemid 41323740)
45. Lu R, Au WC, Yeow WS, Hageman N, Pitha PM. Regulation of the promoter activity of interferon regulatory factor-7 gene. Activation by interferon snd silencing by hypermethylation. J Biol Chem 2000;275:31805-12.
46. Kulaeva OI, Draghici S, Tang L, Kraniak JM, Land SJ, Tainsky MA. Epigenetic silencing of multiple interferon pathway genes after cellular immortalization. Oncogene 2003;22:4118-27. (Pubitemid 36819652)
47. Tomimaru Y, Eguchi H, Wada H, Noda T, Murakami M, Kobayashi S, et al. Insulin-like growth factor-binding protein 7 alters the sensitivity to interferon-based anticancer therapy in hepatocellular carcinoma cells. Br J Cancer 2010;102:1483-90.
48. Tomokuni A, Eguchi H, Tomimaru Y,Wada H, Kawamoto K, Kobayashi S, et al. miR-146a suppresses the sensitivity to interferon-alpha in hepatocellular carcinoma cells. Biochem Biophys Res Commun 2011;414:675-80.